Displaying 601 - 620 of 853
| Active Ingredient | SODIUM HYALURONATE |
| Therapeutic Class | EENT DRUGS MISCELLANEOPUS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | GASTROINTESTINAL DRUGS |
| Therapeutic Class | GASTROINTESTINAL DRUGS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ANTIDIARRHOEAL |
| Therapeutic Class | ANTIDIARRHEA AGENTS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | DIPHENOXYLATE | ATROPINE |
| Therapeutic Class | ANTIDIARRHEA AGENTS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | LOPERAMIDE |
| Therapeutic Class | ANTIDIARRHEA AGENTS |
| Indications | Acute and chronic diarrhea, reduction of the volume of colostomies or ileostomies discharge. |
| Caution | Abdominal pain or bloating, urinary retention, dry mouth. Not recommended for children under 2 years. |
| Dose Range | Acute Diarrhea: Adult and Children 12 years and over: 4mg initially then 2mg after each loose stool to a maximum of 16mg daily ; usual daily dose 6-8mg. Pediatric 4-8 yrs: 1mg 3-4 times daily for 3 days only ; 8-12 yrs: 2mg 4 times daily for up to 5 |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ANTIFLATUENTS |
| Therapeutic Class | ANTIFLATULENTS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | SIMETHICONE |
| Therapeutic Class | ANTIFLATULENTS |
| Indications |
For symptomatic treatment of gastrointestinal distress due to entrapment of gas. Colic in children. |
| Caution | |
| Dose Range | Pediatric: 0.5-1ml with or after feeds. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | CATHARTICS |
| Therapeutic Class | CATHARTICS AND LAXATIVES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | GLYCERINE |
| Therapeutic Class | CATHARTICS AND LAXATIVES |
| Indications | Laxative. Useful for lower bowel evacuation. |
| Caution | Suppository does not have to melt to produce laxative action. |
| Dose Range |
Insert one suppository high into rectum and retain for 15 minutes when bowel movement is required. Moisten with water before use. See BDS supply protocols pg. 6. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | PSYLLIUM |
| Therapeutic Class | CATHARTICS AND LAXATIVES |
| Indications | Constipation. |
| Caution | May cause flatulence and intestinal obstruction. Take with full glass of water to minimise obstruction. Exercise caution in patients with ulcerative colitis. |
| Dose Range | 1 rounded teasp oonful stirred in glass of water 1-2 times daily . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | SODIUM BIPHOSPHATE | SODIUM PHOSPHATE |
| Therapeutic Class | CATHARTICS AND LAXATIVES |
| Indications | Bowel clearance before radiological procedures, endoscopy and surgery . |
| Caution | |
| Dose Range | Adult: One as required. Pediatric: One as required. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | WHEAT DEXTRIN |
| Therapeutic Class | CATHARTICS AND LAXATIVES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | DIGESTANTS |
| Therapeutic Class | DIGESTANTS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | PANCREATIC ENZYMES-BILE SALTS |
| Therapeutic Class | DIGESTANTS |
| Indications |
Conditions where pancreatic enzymes are low or absent e.g. chronic pancreatitis, post -pancreatectomy . |
| Caution |
Slight looseness of stools may occur. Take before or with meals. Swallow tablets whole, do not chew or crush before swallowing. |
| Dose Range | Dependant on preparation and condition being treated. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ANTIEMETICS |
| Therapeutic Class | ANTIEMETICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | DIMENHYDRINATE |
| Therapeutic Class | ANTIEMETICS |
| Indications |
Prevention and treatment of nausea, vomiting and the vertigo of motion sickness. |
| Caution | Drowsiness, dry mouth. Patients should be warned against driving or performing other tasks requiring alertness. c.f. prescribing in liver and renal disease p. 13; 28. |
| Dose Range |
Adult: 50-100mg 2-3 times daily to a maximum of 300mg or 6 tabs. in 24 hours. Supp: 50-100mg 2-3 times daily . i.v: 50mg as needed. Pediatric: 2-6 years: 12.5mg;-25mg every 6-8 hours. 6- 12 y ears: 25-50mg 2-3 times daily . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | DRONABINOL |
| Therapeutic Class | ANTIEMETICS |
| Indications | Synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is a More ... |
| Caution | The most frequent adverse effects of dronabinol include abdominal pain, nausea and vomiting, dizziness, euphoria, paranoid reactions, and somnolence. Seizures and seizure-like activity have been repor More ... |
| Dose Range | Nausea and vomiting associated with chemotherapy. Dose is based on body surface area and is determined by the physician. The usual initial oral dose of dronabinol is 5 mg/m2 given 1 to 3 hours before the first dose of the antineoplastic drug with subsequ |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | GRANISETRON |
| Therapeutic Class | ANTIEMETICS |
| Indications |
Management of nausea and vomiting induced by cytotoxic chemotherapy andradiotherapy, treatment of postoperative nausea and vomiting. |
| Caution | Constipation; diarrhoea; headache; insomnia. |
| Dose Range |
Adult: 1 mg, dose to be diluted to 5 mL and given over 30 seconds; maximum 3 mg p er day . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | FAMOTIDINE |
| Therapeutic Class | HISTAMINE RECEPTOR ANTAGONIST |
| Indications | Gastric, duodenal ulcers, GERD and Zollinger Ellison Syndrome. |
| Caution | Headaches, dizziness, constipation. C.f. prescribing in renal disease p. 29. |
| Dose Range | Adult: Gastric/Duodenal Ulcer:40mg at night for 4-8 weeks; maintenance 20mg at night. GERD: 20 mg twice daily for 6 to 12 weeks, or up to 40 mg twice daily if there is oesophageal erosion or ulceration.. Inj:20mg over 2 mins.every 12 hours. Pediatric |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | RANITIDINE |
| Therapeutic Class | HISTAMINE RECEPTOR ANTAGONIST |
| Indications |
Treatment of peptic ulcer disease, GERD and Zollinger Ellison Syndrome. |
| Caution |
See Famotidine. c.f. prescribing in liver and renal disease p. 17; 36. |
| Dose Range |
Adult and children 12 years and over: 150mg twice daily with breakfast or at night; or 300mg as a single dose at night. Maintenance: 150mg at night. i.m/i.v 50mg given slowly over 2 minutes repeated every 6-8 hours. Pediatric 3-12 yrs: |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |